Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02970669 · ClinicalTrials.gov registry record · Phase 4
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
NCT02970669 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 140 participants.
The verdict
NCT02970669, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
Study Summary
The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection fraction.
Interventions
- DRUG enalapril
- DRUG sacubitril/valsartan (LCZ696)
- DRUG matching placebo sacubitril/valsartan (LCZ696)
- DRUG matching placebo enalapril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2016-12-16 |
| Est. Completion | 2018-03-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02970669
The ClinicalTrials.gov registry entry for NCT02970669 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which enalapril is the first listed.
NCT02970669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02970669 about?
NCT02970669 is a clinical study titled "Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.". The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection fraction.
What is the current status of trial NCT02970669?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2016-12-16. Estimated completion is 2018-03-19.
What interventions are being tested in trial NCT02970669?
The interventions under investigation include: enalapril (DRUG), sacubitril/valsartan (LCZ696) (DRUG), matching placebo sacubitril/valsartan (LCZ696) (DRUG), matching placebo enalapril (DRUG).
Who is sponsoring clinical trial NCT02970669?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.